Sign in to view content

Cell Therapies for Atrophic AMD

Allen C Ho, MD FASRS

Video
Published 2020

Related

One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Quantitative Contrast Sensitivity Longitudinal Changes Correlate Better Than Visual Acuity With Geographic Atrophy Progression
John B. Miller, MD
Annual Meeting Talks
2024

Category: Age-Related Macular Degeneration

See more